Media headlines about Immune Design Corp. (NASDAQ:IMDZ) have trended somewhat positive on Saturday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immune Design Corp. earned a news impact score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.8784587038815 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several research firms have recently issued reports on IMDZ. ValuEngine cut shares of Immune Design Corp. from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Wells Fargo & Company cut shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $29.00 to $10.00 in a report on Tuesday, October 17th. Royal Bank Of Canada began coverage on shares of Immune Design Corp. in a report on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price for the company. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Immune Design Corp. currently has a consensus rating of “Buy” and a consensus target price of $14.75.
Immune Design Corp. (IMDZ) traded up 3.80% during trading on Friday, reaching $4.10. 967,848 shares of the company were exchanged. Immune Design Corp. has a 52-week low of $3.78 and a 52-week high of $13.05. The firm’s market cap is $105.04 million. The firm has a 50-day moving average of $9.49 and a 200-day moving average of $8.54.
Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.50 million. On average, equities analysts forecast that Immune Design Corp. will post ($2.29) EPS for the current year.
In related news, major shareholder Leo Guthart acquired 10,000 shares of Immune Design Corp. stock in a transaction dated Monday, September 18th. The stock was bought at an average price of $9.70 per share, with a total value of $97,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Franklin M. Berger acquired 25,000 shares of Immune Design Corp. stock in a transaction dated Wednesday, October 25th. The shares were bought at an average cost of $4.26 per share, with a total value of $106,500.00. Following the transaction, the director now owns 50,000 shares in the company, valued at $213,000. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 2,786,000 shares of company stock valued at $11,535,500. Insiders own 20.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/immune-design-corp-imdz-receives-daily-news-impact-score-of-0-16.html.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.